Based on the potential of NAT10 as a therapeutic target in diseases such as cancer, HGPS and HIV, and the role of Remodelin as small molecule inhibitor of NAT10, we carried out virtual screening of FDA-approved drugs retrieved from Zinc database. Here, NAT10 is linked to Hutchinson-Gilford progeria syndrome.